PEG-IFNα and ribavirin FOR THE TREATMENT OF HEPATITIS B VIRUS

摘要

1. The use of conjugates of PEG-IFNα in combination with ribavirin to obtain a medicinal product intended for the treatment of infection of chronic hepatitis B.! 2. The use according to claim 1, where the PEG-IFN-α2A conjugate of the formula is used as the PEG-IFN-α conjugate! ! where R and R 'are methyl, X is NH, and n and n' are each or both 420 or 520.! 3. The use according to claim 1 or 2, wherein said chronic hepatitis B infection is an HBeAg-negative or HBeAg-positive chronic hepatitis B infection! 4. The use according to claim 3, where the said infection of chronic hepatitis B is an infection of HBeAg-negative chronic hepatitis B.! 5. The use according to claim 1 or 2, where the amount of conjugate PEG-IFNα is from about 33 to 540 μg per week. ! 6. The use according to claim 4, where the amount of ribavirin is from 400 to 1200 mg per day. ! 7. A method for treating chronic hepatitis B infection, which consists in administering an amount of PEG-IFNα conjugate in combination with an amount of ribavirin, which are effective in treating chronic hepatitis B.! 8. The method according to claim 7, where the PEG-IFNα2A conjugate of the formula is used as the PEG-IFNα conjugate! ! where R and R 'are methyl, X is NH, a n and n' each or both are 420 or 520.! 9. The method according to claim 7 or 8, wherein said chronic hepatitis B infection is an HBeAg-negative or HBeAg-positive chronic hepatitis B infection! 10. The method according to claim 9, where the said infection of chronic hepatitis B is an infection of HBeAg-negative chronic hepatitis B.! 11. The method according to claim 7 or 8, where the amount of PEG-IFNα conjugate administered according to the method is from about 33 to 540 μg per week. ! 12. The method according to claim 10, where